Evolution of the Average Target: Valneva SE Pref.

Evolution of the Target Price: Valneva SE Pref.

Changes in Analyst Recommendations: Valneva SE Pref.

94c54c1daecbbf141a8147ebb345.e56AYjSlXIwB8knaoVJFmYVNqaxzIPJFZA6h6bfzCVg.NMHiEXLmBepkvx6w7CV228oFxfonVqMsUWXZpcSJR2AV6vEVTugS-nLEcQ~dfdbcb1755b061ab78737c5080491766
08-11 TD Cowen Initiates Valneva at Buy Rating, With $12 Price Target MT
05-13 French Analyst Ratings: Aramis and Valneva penalized following profit warnings Zonebourse
04-30 Schneider Electric, Capgemini, Societe Generale... stocks to watch today in Paris Zonebourse
04-22 Goldman Sachs Downgrades Valneva to Sell From Neutral, Adjusts Price Target to $4.90 From $7.50 MT
04-22 French Analyst Ratings: Thales, Vallourec and Valneva in the Spotlight Zonebourse
03-18 Valneva heads for fourth consecutive gain following annual results Zonebourse
01-20 Stifel Reiterates Buy Rating and Price Target on Valneva Zonebourse
01-06 Valneva, Biggest Gainer on SBF 120 and SRD at Close of Tuesday, January 6, 2026 Zonebourse
01-06 Valneva Surges on Positive Broker Comments Zonebourse
01-06 CAC 40 Lags Behind; Valneva in Demand Zonebourse
01-06 Valneva Posts Strongest Midday Gain on SBF 120, Tuesday, January 6, 2026 Zonebourse
01-06 Stock of the Day in Paris – Valneva Bolstered by Stifel Zonebourse
01-06 Stifel Raises Price Target for Valneva Zonebourse
01-06 Analysts' calls of the day: Bernstein favors Thales over BAE Systems and Dassault Aviation Zonebourse
11-20 Stifel Reiterates Buy Recommendation on Valneva Zonebourse
11-04 Valneva SE Announces Positive Results of Its Phase 1 Clinical Trial Investigating the Safety and Immunogenicity of VLA1601 CI
25-09-03 Valneva publishes positive data for its Lyme disease vaccine candidate, stock rises RE
25-08-26 Valneva: Stifel Adjusts Price Target Following FDA Suspension of Ixchiq License Zonebourse
25-08-26 Valneva: Stifel adjusts target price Zonebourse
25-08-12 Valneva: Oddo BHF confirms 'outperform' rating Zonebourse
25-07-14 Valneva Shares Surge After EMA Lifts Restriction on Chikungunya Vaccine RE
24-08-13 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
24-06-24 Valneva rises after Canadian approval for its chikungunya vaccine RE
24-02-05 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
24-01-02 Valneva: Oddo BHF remains positive Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+16.67%
+18.87%
+5.13%
+17.84%
+39.5%
-3.13%
+27.58%
+0.23%
-3.6%
Average +13.23%
Weighted average by Cap. +15.69%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.796EUR
Average target price
6.193EUR
Spread / Average Target
+121.49%
High Price Target
12.00EUR
Spread / Highest target
+329.18%
Low Price Target
2.150EUR
Spread / Lowest Target
-23.10%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
Global
Quality
ESG MSCI
-
  1. Stock Market
  2. Stocks
  3. VLA Stock
  4. VLAP Stock
  5. Consensus Valneva SE Pref.